Postexposure prophylaxis for occupational exposure to selected pathogens for healthcare personnel
- 7 June 2024
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 37 (4) , 296-303
Abstract
Purpose of review: Timely postexposure prophylaxis is important after an occupational exposure. Here we review select organisms, exposure opportunities in the healthcare setting, and postexposure prophylaxis regimens. Recent findings: Needlestick injuries pose a risk of exposure to bloodborne pathogens, such as HIV, Hepatitis B, and Hepatitis C. Risk mitigation strategies should be reexamined in light of newer vaccines and therapeutics. Increased vaccine hesitancy and vaccine denialisms may foster the re-emergence of some infections that have become extremely uncommon because of effective vaccines. With increasing occurrences of zoonotic infections and the ease of global spread as evidenced by COVID-19 and mpox, healthcare exposures must also consider risks related to emerging and re-emerging infectious diseases. Summary: Early recognition and reporting of occupational exposures to pathogens with available postexposure prophylaxis is key to mitigating the risk of transmission. Providers should be able to evaluate the exposure and associated risks to provide prompt and appropriate postexposure prophylaxis.Keywords
This publication has 25 references indexed in Scilit:
- Seroprevalence of tetanus and pertussis antibodies among health care workers in Wuhu, ChinaHuman Vaccines & Immunotherapeutics, 2024
- Efficacy of different AV7909 dose regimens in a nonclinical model of pulmonary anthraxHuman Vaccines & Immunotherapeutics, 2023
- Single visit rabies pre-exposure prophylaxis: A literature reviewTravel Medicine and Infectious Disease, 2023
- Immunogenicity and Protective Efficacy of Recombinant Protective Antigen Anthrax Vaccine (GC1109) in A/J Mice ModelVaccine, 2023
- An alternative route to pertussis protection?The Lancet, 2023
- Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus–diphtheria–acellular pertussis vaccine: a randomised, double-blind, phase 2b trialThe Lancet, 2023
- Monoclonal antibodies against rabies: current uses in prophylaxis and in therapyCurrent Opinion in Virology, 2022
- Advances in the progress of monoclonal antibodies for rabiesHuman Vaccines & Immunotherapeutics, 2022
- The WHO position on rabies immunization – 2018 updatesVaccine, 2019
- A Case–Control Study of HIV Seroconversion in Health Care Workers after Percutaneous ExposureNew England Journal of Medicine, 1997